PMGC (ELAB) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
PRF Technologies is the larger company by market cap ($1.7 million vs $1.3 million), about 1.2 times the size. PMGC converts more of its revenue into profit, with a net margin of -1313.0% versus -29541.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELAB | PRFX |
|---|---|---|
| Share price | $1.14 | $0.4758 |
| Market cap | $1.33M | $1.66M |
| 1-day change | -10.24% | -23.68% |
| EPS (TTM) | $-555.60 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $590.08K | $17.00K |
| Net income (latest FY) | $-7.75M | $-5.02M |
| Gross margin | 31.40% | -311.76% |
| Operating margin | — | -30129.41% |
| Net margin | -1313.00% | -29541.18% |
| 52-week high | $1,344.00 | $7.95 |
| 52-week low | $1.14 | $0.46 |
| Distance from 52-week high | -99.92% | -94.02% |
| Average volume | 279.01K | 228.55K |
| Shares outstanding | 1.17M | 3.50M |
| Employees | 32 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PMGC is more profitable, keeping -1313.0 cents of every revenue dollar as net income versus -29541.2 cents for PRF Technologies.
About PMGC
ELAB stock →PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
ELAB vs PRFX FAQ
Which is bigger, PMGC or PRF Technologies?
PRF Technologies (PRFX) is larger, with a market capitalization of $1.66M compared with $1.33M for PMGC (ELAB).
Are PMGC and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.